Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
28-week open-label extension safety study of flibanserin in premenopausal women with hypoactive sexual desire disorder
2007-004076-38Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of flibanserin in hypoactive sexual desire disorder (HSDD), sponsored by Boehringer Ingelheim. Primary endpoints: Proportion of patients with common expected adverse events, Discontinuations due to adverse events and 1 more. Started Oct 2007; status: completed.
02
Drugs
flibanserin
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on 2007-004076-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004076-38.